Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Core Insights - Nektar Therapeutics is emerging as a significant player in the immunodermatology sector, particularly with its recent Phase 2b data from the REZOLVE-AD trial [1] Group 1: Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on immunodermatology [1] Group 2: Recent Developments - The company reported Phase 2b data from the REZOLVE-AD trial on June 24, showcasing the potential of Rezpeg, a first-in-class treatment [1]